Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Seleniun/cancer claim

This article was originally published in The Tan Sheet

Executive Summary

Supplement maker Wellness Lifestyles d/b/a American Longevity seeks FDA approval of health claims stating selenium "may reduce the risk of certain cancers" and "may produce anticarcinogenic effects in the body." Petition filed July 10 notes claims "do not identify specific intake quantities for selenium," although studies have shown risk reduction with 50-200 mcg/day. Adult daily intake below 900 mcg "is unlikely to cause adverse reactions," Wellness adds. Petition cites six human clinical trials (three in China, and one each in U.S., India, Italy) on selenium supplementation and cancer incidence. Firm is represented by Emord & Associates (Washington, D.C.), which filed a health claim petition for phosphatidylserine and cognitive dysfunction/dementia in April (1"The Tan Sheet" May 6, 2002, p. 10)...
Advertisement

Related Content

Phosphatidylserine, Dementia, Cognitive Decline Health Claim Sought
Phosphatidylserine, Dementia, Cognitive Decline Health Claim Sought

Topics

Advertisement
UsernamePublicRestriction

Register

PS094283

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel